Pharmaceuticals 26 May 2026 - 2 June 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares rose 1.4% to $233.11 by early afternoon Tuesday, bucking a sharp drop in biotech ETFs. Investors traded on anticipation of management meetings and the pending $739 million XOMA Royalty acquisition. XOMA shares slipped 0.3%. The Ligand-XOMA deal still requires shareholder approval and could face delays.
June 2, 2026
MediWound Shares Slide This Week; BARDA Moves in Focus
····

MediWound Shares Slide This Week; BARDA Moves in Focus

MediWound Ltd. shares fell 1.6% Friday to $14.33, down 13.6% since May 22, after first-quarter revenue dropped to $1.5 million from $4.0 million a year earlier. Net loss widened to $3.0 million. The company maintained its 2026 revenue forecast, expecting most sales later in the year. CEO Ofer Gonen cited slow enrollment in the EscharEx VALUE trial and anticipated second-half revenue from government contracts.
May 30, 2026
Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching
····

Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching

Cumberland Pharmaceuticals shares rose 21 cents to $6.15 after announcing the launch of its Vibativ antibiotic in China through SciClone Pharmaceuticals. The move follows last month’s $100 million deal to sell its U.S. branded portfolio to Apotex. Cumberland’s market value stood at about $92 million. Investors are watching for shareholder approval of the Apotex deal and demand for Vibativ in China.
May 29, 2026
vTv Therapeutics Drops as Diabetes Study Date Approaches
····

vTv Therapeutics Drops as Diabetes Study Date Approaches

vTv Therapeutics shares fell 1.1% to $33.14 Friday afternoon, underperforming biotech indexes as investors await updates on its diabetes drug cadisegliatin. The company last reported on May 13, saying Phase 3 CATT1 enrollment remains on track for Q3 2026. Cash reserves rose to $98.1 million at March 31 after a $20 million licensing payment. No new filings or press releases have been issued since the quarterly report.
May 29, 2026
Aurinia Stock Dips as Traders Eye Lupkynis Data
····

Aurinia Stock Dips as Traders Eye Lupkynis Data

Aurinia Pharmaceuticals shares fell 0.9% to $15.21 in late morning Nasdaq trading Friday, underperforming the broader biotech sector. Investors focused on Lupkynis sales and the upcoming June 3 shareholder meeting, with no new company news released. The company relies on Lupkynis as its only approved drug and faces competition from GSK’s Benlysta and Genentech’s Gazyva.
May 29, 2026
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference
····

Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference

Pliant Therapeutics shares rose 1.2% to $1.25 in late trading Thursday, with volume over 210,000 shares and a market cap near $77 million. The move came ahead of new data set for release May 30 at ASCO from the Phase 1b FORTIFY trial of PLN-101095 in checkpoint-inhibitor-refractory solid tumors. Pliant reported a Q1 net loss of $20 million and held $172.4 million in cash as of March 31.
May 29, 2026
Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
····

Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing

Viking Therapeutics shares rose 1.7% to $32.19 after Lake Street initiated coverage with a Buy rating and an $89 price target, citing potential for its obesity drug VK2735. Phase 2 trial data showed up to 12.2% mean weight loss in 13 weeks. The company’s market cap stood at $3.72 billion. Board elections and auditor approval were disclosed in a May 26 SEC filing.
May 28, 2026
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus
····

NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus

NewAmsterdam Pharma shares rose 1.3% to $36.56 Wednesday after Chief Accounting Officer Louise Frederika Kooij exercised and sold 65,000 shares, according to a Form 4 filing. A separate Form 144 listed a proposed sale of 210,000 shares for Kooij. The company awaits key regulatory decisions on its cholesterol drug obicetrapib later this year. NewAmsterdam reported a first-quarter net loss of $48.4 million.
May 28, 2026
Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug
····

Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug

Maze Therapeutics shares slipped 1.2% to $26.05 in early Nasdaq trading Thursday, valuing the company near $1.4 billion. CEO Jason Coloma will present at Jefferies and Goldman Sachs healthcare conferences in June, where investors expect updates on the MZE829 kidney drug program. Maze reported $528 million in cash after an April stock sale and aims to start another Phase 2 study mid-year.
May 28, 2026
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech
····

Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech

Phio Pharmaceuticals shares rose 1.39% to $1.095 Wednesday as the company prepared to present its PH-762 skin-cancer program at a virtual investor event. CEO Robert Bitterman will discuss the INTASYL platform and Phase 1b results, which showed a 65% response rate among cutaneous squamous cell carcinoma patients. Phio plans to seek FDA feedback on its next trial design in Q2 2026. Market cap stood near $12.55 million.
May 27, 2026
Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race
····

Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race

Arrowhead Pharmaceuticals shares rose 5% to $78.68 Tuesday after new plozasiran data supported use in patients with moderate kidney or liver issues. The company’s market cap reached $11.2 billion. Arrowhead reported $73.7 million in quarterly revenue and a net loss of $132.7 million. Rival Sobi released Phase 3 data on olezarsen the same day.
May 27, 2026
United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone
····

United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone

United Therapeutics shares rose 1.4% to $576.30 Tuesday after reporting Phase 3 trial data showing Tyvaso improved lung function and reduced risk of worsening in idiopathic pulmonary fibrosis. The company plans to file for FDA approval by summer’s end. Revenue fell 2% last quarter to $781.5 million, with Tyvaso sales slipping. Liquidia’s rival drug Yutrepia posted $130 million in Q1 sales after last year’s FDA nod.
May 26, 2026
BridgeBio shares slip as 2031 drug pricing risk pops up
····

BridgeBio shares slip as 2031 drug pricing risk pops up

BridgeBio Pharma shares fell 2.8% to $67.18 after Raymond James downgraded the stock, citing payer-driven risks for its heart drug Attruby. The downgrade follows concerns that insurers may favor cheaper generics as Pfizer’s Vyndamax nears loss of exclusivity in 2031. BridgeBio reported $194.5 million in Q1 revenue, mostly from Attruby, and approved a $500 million buyback. The stock lagged biotech sector gains Tuesday.
May 26, 2026
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break
····

Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break

Adial Pharmaceuticals shares fell 1.4% to $2.05 in premarket trading Tuesday, after U.S. exchanges closed Monday for Memorial Day. The company reported $4.6 million in cash as of March 31, enough to fund operations into the second half of 2026. No new company updates were released over the holiday weekend. Plans for a new Phase 3 trial of lead drug AD04 remain on hold pending additional funding.
May 26, 2026
Roivant stock set for new test after big move on drug data
·····

Roivant stock set for new test after big move on drug data

Roivant Sciences shares rose 1.2% to $30.31 in light premarket trading Tuesday after last week’s 14% surge on positive IMVT-1402 drug data. Immunovant, developing the autoimmune drug, jumped 31% last week despite reporting a larger loss than expected. BofA raised its price target to $31.50 but kept a Neutral rating, while Citi and TD Cowen lifted targets and maintained Buy calls. U.S. markets reopened after the Memorial Day holiday.
May 26, 2026
1 2 3 4